Indication
Adult Acute Myeloid Leukemia (AML)
11 clinical trials
20 products
10 drugs
Clinical trial
An Investigator-Sponsored Randomized Phase II Study of Selinexor in Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia PatientsStatus: Recruiting, Estimated PCD: 2025-06-01
Product
CytarabineProduct
DaunorubicinDrug
SelinexorClinical trial
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous LeukemiaStatus: Completed, Estimated PCD: 2023-04-17
Drug
sirolimusProduct
MitoxantroneProduct
EtoposideClinical trial
A Feasibility Study of Organ-Sparing Marrow-Targeted Irradiation (OSMI) to Condition Patients With High-Risk Hematologic Malignancies Prior to Allogeneic Hematopoietic Stem Cell TransplantationStatus: Completed, Estimated PCD: 2022-09-06
Drug
cyclophosphamideProduct
Anti-thymocyte globulinDrug
tacrolimusDrug
methotrexateClinical trial
Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell NeoplasmStatus: Active (not recruiting), Estimated PCD: 2024-12-15
Drug
fludarabineClinical trial
Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CMLStatus: Recruiting, Estimated PCD: 2025-05-31
Product
CladribineClinical trial
Four-Arm Randomized Phase II Study of SGI-110: 5 Days, Versus 10 Days, Versus 5 Days + Idarubicin, Versus 5 Days + Cladribine, in Previously Untreated Patients >/= 70 Years With Acute Myeloid LeukemiaStatus: Completed, Estimated PCD: 2020-11-24
Product
GuadecitabineProduct
IdarubicinClinical trial
A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell TransplantStatus: Completed, Estimated PCD: 2024-02-02
Product
GilteritinibProduct
MidostaurinProduct
VenetoclaxClinical trial
Rituximab For Prevention Of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT)Status: Terminated, Estimated PCD: 2012-12-19
Drug
rituximabProduct
FludarabineDrug
busulfanProduct
Immunosuppressive therapyClinical trial
A Phase II Study of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (Tasigna) (DATA) in Patients Newly Diagnosed With Acute Myeloid Leukemia and KIT OverexpressionStatus: Completed, Estimated PCD: 2017-07-31
Product
NilotinibClinical trial
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous LeukemiaStatus: Completed, Estimated PCD: 2019-12-12
Clinical trial
A Phase III Study of Daunorubicin and Cytarabine +/- G3139 (Genasense, Oblimersen Sodium, NSC #683428, IND #58842), a BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients With Acute Myeloid Leukemia (AML) > / = 60 YearsStatus: , Estimated PCD: 2007-06-01
Product
OblimersenDrug
cytarabine